Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2D | O15399 | 2/20 | 0.57 |
| ▸ | GRIN3B | O60391 | 2/20 | 0.57 |
| ▸ | GRIA1 | P42261 | 2/20 | 0.57 |
| ▸ | GRIA2 | P42262 | 2/20 | 0.57 |
| ▸ | GRIA3 | P42263 | 2/20 | 0.57 |
| ▸ | GRIA4 | P48058 | 2/20 | 0.57 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.57 |
| ▸ | GRIN2A | Q12879 | 2/20 | 0.57 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.57 |
| ▸ | GRIN2C | Q14957 | 2/20 | 0.57 |
| ▸ | GRIN3A | Q8TCU5 | 2/20 | 0.57 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.49 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.44 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Eticyclidine SCHEMBL10669385 | 0.98 | GRIN2D (0.58) | GRIN2DGRIN3BGRIA1GRIA2GRIA3 | |
| Eticyclidine SCHEMBL7258514 | 0.93 | GRIN2D (0.51) | GRIN2DGRIN3BGRIA1GRIA2GRIA3 | |
| Eticyclidine SCHEMBL8452334 | 0.90 | GRIN2D (0.49) | GRIN2DGRIN3BGRIA1GRIA2GRIA3 | |
| SCHEMBL469195 | 0.90 | OPRM1 (0.48) | GRIN2DGRIN3BGRIA1GRIA2GRIA3 | |
| Eticyclidine SCHEMBL5789720 | 0.86 | GRIN2D (0.46) | GRIN2DGRIN3BGRIA1GRIA2GRIA3 | |
| SCHEMBL30534232 | 0.85 | GRIN2D (0.62) | GRIN2DGRIN3BGRIA1GRIA2GRIA3 | |
| Eticyclidine SCHEMBL29055231 | 0.85 | GRIN2D (0.45) | GRIN2DGRIN3BGRIA1GRIA2GRIA3 | |
| SCHEMBL5328724 | 0.82 | GRIN2D (0.68) | GRIN2DGRIN3BGRIA1GRIA2GRIA3 | |
| SCHEMBL15947412 | 0.82 | DPP4 (0.42) | GRIN2DGRIN3BGRIA1GRIA2GRIA3 | |
| SCHEMBL22564356 | 0.82 | DPP4 (0.42) | GRIN2DGRIN3BGRIA1GRIA2GRIA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 922 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12539337-B2 | Nanostructure conjugates for modulation of location-specific subtypes of receptors and ion channels | Molokanova, Elena (US) | 2026-02-03 | — | — | US | claimed |
| EP-4629989-A2 | TREATMENT OR PREVENTION OF DEPRESSIVE DISORDERS THROUGH COMBINATION THERAPY | Freedom Biosciences, Inc. (US) | 2025-10-15 | — | — | EP | claimed |
| US-20250161264-A1 | (AMPAR-PAM)-NMDA RECEPTOR ANTAGONIST COMBINATION THERAPY FOR TREATMENT OF MENTAL CONDITIONS AND DISORDERS | GILGAMESH PHARMACEUTICALS, INC. | 2025-05-22 | — | — | US | claimed |
| US-20240350433-A1 | TREATMENT COMPOSITIONS AND METHODS | UNIV YALE (US) | 2024-10-24 | — | — | US | claimed |
| WO-2024123935-A2 | TREATMENT OR PREVENTION OF DEPRESSIVE DISORDERS THROUGH COMBINATION THERAPY | FREEDOM BIOSCIENCES, INC. (US) | 2024-06-13 | — | — | WO | claimed |
| US-20240066003-A1 | NEURODEVELOPMENTAL DISORDER THERAPY | ANAVEX LIFE SCIENCES CORP. (US) | 2024-02-29 | — | — | US | claimed |
| EP-4288429-A1 | LACTAMS AS CBL-B INHIBITORS | Genentech, Inc. (US) | 2023-12-13 | — | — | EP | claimed |
| EP-4247340-A1 | COMPLEXING AGENT SALT FORMULATIONS OF PHARMACEUTICAL COMPOUNDS | Bexson Biomedical, Inc. (US) | 2023-09-27 | — | — | EP | claimed |
| WO-2023154450-A2 | (AMPA-PAM)-NMDA RECEPTOR ANTAGONIST COMBINATION THERAPY FOR TREATMENT OF MENTAL CONDITIONS AND DISORDERS | GILGAMESH PHARMACEUTICALS, INC. (US) | 2023-08-17 | — | — | WO | claimed |
| WO-2023114529-A2 | PHARMACOACTIVE FORMULATIONS FOR DELIVERY OF PSYCHEDELIC COMPOUNDS | BENNES, INC. (US) | 2023-06-22 | — | — | WO | claimed |
| US-20010002421-A1 | METHODS FOR IN VITRO SUSCEPTIBILITY TESTING OF CHLAMYDIA | STRATTON CHARLES W (US) | 2001-05-31 | — | — | US | claimed |
| US-6107002-A | Reducing resist shrinkage during device fabrication | MICRON TECHNOLOGY, INC. (US) | 2000-08-22 | — | — | US | claimed |
| US-6071629-A | FACING ADHESION FOR RUSTPROOFING, ZINC OR ZINC ALLOY LAYER AND ORGANIC RESIN | MITSUI MINING & SMELTING CO., LTD. (JP) | 2000-06-06 | — | — | US | claimed |
| EP-0981372-A2 | COMPOSITIONS OF ANTICHLAMYDIAL AGENTS FOR THE DIAGNOSIS AND MANAGEMENT OF INFECTION CAUSED BY CHLAMYDIA | VANDERBILT UNIVERSITY (US) | 2000-03-01 | — | — | EP | claimed |
| WO-1998050074-A2 | COMPOSITIONS OF ANTICHLAMYDIAL AGENTS FOR THE DIAGNOSIS AND MANAGEMENT OF INFECTION CAUSED BY CHLAMYDIA | VANDERBILT UNIVERSITY (US) | 1998-11-12 | — | — | WO | claimed |
| EP-0507672-B1 | N-cyclohexyl benzamides derivatives, preparations and therapeutic applications thereof | LOGEAIS LABOR JACQUES (FR) | 1997-06-04 | — | — | EP | claimed |
| US-5492792-A | OPTICAL CARD OR DISKS; EXCELLENT LIGHT SENSITIVITY WITHIN NEAR INFRARED REGION AND HEAT RESISTANCE; STORE INFORMATIONSAT HIGH DENSITY | CANON KABUSHIKI KAISHA (JP) | 1996-02-20 | — | — | US | claimed |
| US-5428074-A | Using an amine salt solution | CUTLER FRANCES M (US) | 1995-06-27 | — | — | US | claimed |
| US-5081159-A | Mixture of anionic and cationic resins, controlling density of salt solution causing anionic resin to float | CUTLER FRANCES M (US) | 1992-01-14 | — | — | US | claimed |
| US-4147514-A | Test means and method for detecting ketone bodies | MILES LABORATORIES, INC. (US) | 1979-04-03 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12539337-B2 | Nanostructure conjugates for modulation of location-specific subtypes of receptors and ion channels | GRIN2B, GRIN2A, GRIN3A | GRIN2D 6/4885GRIN3B 8/4885GRIA1 93/4885 |
| US-20250161264-A1 | (AMPAR-PAM)-NMDA RECEPTOR ANTAGONIST COMBINATION THERAPY FOR TREATMENT OF MENTAL CONDITIONS AND DISORDERS | GRIN2A, GRIN1, GRIN3A | GRIN2D 12/4885GRIN3B 9/4885GRIA1 20/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.